Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | LOX | P28300 | 1/20 | 0.33 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24529151 | 1.00 | TSHR (0.37) | TSHRSLC1A2ALDH1A1TDP1LOX | |
| SCHEMBL18996844 | 0.88 | TSHR (0.35) | TSHRSLC1A2ALDH1A1TDP1LOX | |
| SCHEMBL20919216 | 0.74 | — | — | |
| SCHEMBL5220284 | 0.74 | TSHR (0.40) | TSHRSLC1A2ALDH1A1TDP1LOX | |
| SCHEMBL4918992 | 0.71 | TSHR (0.34) | TSHRSLC1A2ALDH1A1TDP1LOX | |
| SCHEMBL4288456 | 0.70 | TSHR (0.48) | TSHRALDH1A1TDP1 | |
| SCHEMBL27969711 | 0.69 | TSHR (0.46) | TSHRSLC1A2ALDH1A1TDP1LOX | |
| SCHEMBL6608456 | 0.69 | TSHR (0.46) | TSHRSLC1A2ALDH1A1TDP1LOX | |
| SCHEMBL31266480 | 0.68 | TSHR (0.41) | TSHRALDH1A1TDP1 | |
| SCHEMBL24529143 | 0.67 | KIF11 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4262788-B1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-03-28 | — | — | US | disclosed |
| WO-2022132696-A1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, UTS2R | TSHR 197/4885SLC1A2 211/4885ALDH1A1 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.